Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole vs olanzapine vs risperidone in schizophrenia
IRCT20150822023705N17Phase 3Recruiting
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Aripiprazole, Risperidone and Olanzapine (3 arms). Primary endpoints: Body mass index and Efficacy of aripiprazole, olanzapine and risperidone. Started Aug 2026; status: recruiting.
02
Drugs
aripiprazoleolanzapinerisperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20150822023705N17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150822023705N17.